Spruce biosciences announces topline results from cahmelia-204 in adult cah and cahptain-205 in adult and pediatric cah

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its cahmelia-204 study of tildacerfont in adult cah and its cahptain-205 study of tildacerfont in adult and pediatric cah. “we are very grateful to all the patients, families, investigators, and the e.
CAH Ratings Summary
CAH Quant Ranking